Trial reportPloS one2025
Association of predicted lean body mass and fat mass with prognosis in patients with heart failure preserved ejection fraction.
Trial report in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have shown that body composition influences the prognosis of heart failure patients; however, the prognostic value of lean body mass and fat mass in patients with heart failure with preserved ejection fraction (HFpEF) remains unclear. This study aimed to investigate the association of lean body mass index and fat mass index with the prognostic outcomes in patients with HFpEF.
methodsWe performed a post hoc analysis of data from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial to assess the relationship between Lean BMI and FMI with the adverse events. The primary endpoint was defined as a composite of cardiovascular death, aborted cardiac arrest, or heart failure hospitalization.
resultsA total of 3,320 patients were included, with a median follow-up of 3.3 years. Among them, 624 occurred a primary endpoint event, and 503 died. Lean BMI was not associated with the primary endpoint (HR 0.98, 95% CI 0.82-1.16) but was found to reduce the risk of all-cause mortality (HR 0.74, 95% CI 0.61-0.91). In contrast, FMI was associated with an increased risk of both the primary endpoint (HR 1.29, 95% CI 1.09-1.55) and all-cause mortality (HR 1.46, 95% CI 1.19-1.79).
conclusionIn patients with HFpEF, a higher FMI was strongly associated with increased risks of both the primary endpoint and all-cause mortality, while an elevated LBMI was associated with a reduced risk of mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.